Mélanome malin leptoméningé primitif : une étiologie rare de pachy- et leptoméningite

Bocquillon, P.; Berteloot, Anne-Sophie; Maurage, Claude‐Alain; Mackowiak‐Cordoliani, Marie‐Anne; Pasquier, Florence; Bombois, Stéphanie

doi:10.1016/j.neurol.2010.03.011

Cited by 7 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic chemotherapy is the mainstay of treatment for advanced CNS melanoma. The median progression‐free survival (PFS) for patients receiving systemic chemotherapy is approximately 5 months, and the median overall survival (OS) is around 12.5 months (Allcutt et al., 1993; Bocquillon et al., 2010; Hsieh et al., 2015b; Martin‐Blondel et al., 2009b; Pan et al., 2014b; Rosenthal et al., 2003c; Sagiuchi et al., 2002b; Salisbury & Rose, 1989; Tosaka et al., 2001; Williams, 1969). Currently, chemotherapy regimens for primary CNS melanoma have not been standardized, and clinical practice relies on physicians' experience with similar cases and their assessment of the pros and cons.…”

Section: Treatmentmentioning

confidence: 99%

Clinicopathological features, current status, and progress of primary central nervous system melanoma diagnosis and treatment

Guo,

Wei,

Guo

et al. 2023

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

Primary central nervous system (CNS) melanoma is an extremely rare condition, with an incidence rate of 0.01 per 100,000 individuals per year. Despite its rarity, the etiology and pathogenesis of this disease are not yet fully understood. Primary CNS melanoma exhibits highly aggressive biological behavior and presents clinically in a distinct manner from other types of melanomas. It can develop at any age, predominantly affecting the meninges as the primary site, with clinical symptoms varying depending on the neoplasm’s location. Due to the lack of specificity in its presentation and the challenging nature of imaging diagnosis, distinguishing primary CNS melanoma from other CNS diseases. The combination of challenges in early detection, heightened tumor aggressiveness, and the obscured location of its origin contribute to an unfavorable prognostic outcome. Furthermore, there has been currently no consensus on a standardized treatment approach for primary CNS melanoma. Despite recent advancements in targeted therapy and immunotherapy for CNS melanoma, patients with primary CNS melanoma have limited treatment options due to their inadequate response to these therapies. Here, we provided a comprehensive summary of the epidemiology, clinical features, molecular pathological manifestations, and available diagnostic and therapeutic approaches of primary CNS melanoma. Additionally, we proposed potential therapeutic strategies for it.

show abstract